Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBM-C101 in HPV16/18 Infection
NCT07714577Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Jul 2026
- Primary completion
- Aug 2030
01
Overview
Open-label, single-arm trial of BBM-C101 in human papillomavirus infection, sponsored by Tianjin First Central Hospital. Primary endpoint: Safety and Tolerability of BBM040 Injection at 52 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
BBM-C101
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT07714577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714577.